bw 306u has been researched along with Smoking Cessation in 5 studies
hydroxybupropion: active metabolite of bupropion; structure in first source
Smoking Cessation: Discontinuing the habit of SMOKING.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In African American light smokers with verified early bupropion use, genetically normal CYP2B6 activity appears to be indirectly associated with greater smoking cessation success in a relationship mediated by higher hydroxybupropion concentration." | 9.51 | Does sex alter the relationship between CYP2B6 variation, hydroxybupropion concentration and bupropion-aided smoking cessation in African Americans? A moderated mediation analysis. ( Ahluwalia, JS; Benowitz, NL; Chenoweth, MJ; Cox, LS; Knight, J; Nollen, NL; Peng, AR; Swardfager, W; Tyndale, RF; Zhu, AZX, 2022) |
| "Bupropion is used for treatment of depression during pregnancy." | 7.83 | Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid. ( Ahmed, MS; Clark, SM; Fokina, VM; Hankins, GD; Nanovskaya, TN; Oncken, C; West, H, 2016) |
| "In African American light smokers with verified early bupropion use, genetically normal CYP2B6 activity appears to be indirectly associated with greater smoking cessation success in a relationship mediated by higher hydroxybupropion concentration." | 5.51 | Does sex alter the relationship between CYP2B6 variation, hydroxybupropion concentration and bupropion-aided smoking cessation in African Americans? A moderated mediation analysis. ( Ahluwalia, JS; Benowitz, NL; Chenoweth, MJ; Cox, LS; Knight, J; Nollen, NL; Peng, AR; Swardfager, W; Tyndale, RF; Zhu, AZX, 2022) |
| "Bupropion is used for treatment of depression during pregnancy." | 3.83 | Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid. ( Ahmed, MS; Clark, SM; Fokina, VM; Hankins, GD; Nanovskaya, TN; Oncken, C; West, H, 2016) |
| "Preclinical studies with bupropion in rodent models of nicotine dependence have generated equivocal findings with regard to translating the clinical efficacy of the antidepressant as a smoking cessation agent." | 3.81 | Examination of the metabolite hydroxybupropion in the reinforcing and aversive stimulus effects of nicotine in rats. ( Blough, B; Carroll, FI; Damaj, MI; Malcolm, E; Shoaib, M, 2015) |
| "Although the antidepressant bupropion is prescribed to aid in smoking cessation, little is known concerning its mechanisms of action in this regard." | 3.78 | Bupropion and its main metabolite reverse nicotine chronic tolerance in the mouse. ( Carroll, FI; Damaj, MI; Grabus, SD, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chenoweth, MJ | 1 |
| Peng, AR | 1 |
| Zhu, AZX | 1 |
| Cox, LS | 1 |
| Nollen, NL | 1 |
| Ahluwalia, JS | 1 |
| Benowitz, NL | 1 |
| Knight, J | 1 |
| Swardfager, W | 1 |
| Tyndale, RF | 1 |
| Malcolm, E | 1 |
| Carroll, FI | 2 |
| Blough, B | 1 |
| Damaj, MI | 2 |
| Shoaib, M | 1 |
| Fokina, VM | 1 |
| West, H | 1 |
| Oncken, C | 1 |
| Clark, SM | 1 |
| Ahmed, MS | 1 |
| Hankins, GD | 1 |
| Nanovskaya, TN | 1 |
| Teitelbaum, AM | 1 |
| Flaker, AM | 1 |
| Kharasch, ED | 1 |
| Grabus, SD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Enhancing Tobacco Use Treatment for African American Light Smokers[NCT00666978] | Phase 4 | 540 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Salivary cotinine-verified smoking abstinence at 6 months. A cut point of 15 ng/ml was used to differentiate smokers from nonsmokers. (NCT00666978)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bupropion Arm | 36 |
| Placebo Arm | 27 |
We genotyped CYP2B6 in 268 from the Bupropion arm as this polymorphism is related to bupropion metabolism. (NCT00666978)
Timeframe: Week 3
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| CYP2B6*4 Allele Frequency | CYP2B6*5 Allele Frequency | CYP2B6*6 Allele Frequency | CYP2B6*9 Allele Frequency | CYP2B6*16 Allele Frequency | CYP2B6*18 Allele Frequency | CYP2B6*22 Allele Frequency | |
| Bupropion Arm | 2 | 6 | 95 | 0 | 0 | 17 | 6 |
"Analyzed CYP2A6 by genotype. The variants present in people in the slow genotype group include *17, *20, *23,*27, *35, *9, *2, *25, *26, and *4. The fast metabolizers have none of the variant alleles tested.~Slow metabolizers have any reduction or loss of function variant. Fast metabolizers are *1/*1 genotype by exclusion." (NCT00666978)
Timeframe: Week 0
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Slow Metabolizers by Genotype | Fast Metabolizers by Genotype | |
| All Study Participants | 265 | 269 |
"Analyzed CYP2A6 by activity, called the nicotine metabolite ratio using a split between slow and fast metabolism at 0.31.~The variants present in people in the slow genotype group include *17, *20, *23,*27, *35, *9, *2, *25, *26, and *4. The fast metabolizers have none of the variant alleles tested.~Blood samples were collected for 3HC/COT ratio at Week 0." (NCT00666978)
Timeframe: Weeks 0
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Fast Metabolizers by Nicotine Metabolite Ratio | Slow Metabolizers by Nicotine Metabolite Ratio | |
| All Study Participants | 236 | 214 |
1 trial available for bw 306u and Smoking Cessation
| Article | Year |
|---|---|
Does sex alter the relationship between CYP2B6 variation, hydroxybupropion concentration and bupropion-aided smoking cessation in African Americans? A moderated mediation analysis.
Topics: Black or African American; Bupropion; Cytochrome P-450 CYP2B6; Female; Humans; Male; Mediation Analy | 2022 |
4 other studies available for bw 306u and Smoking Cessation
| Article | Year |
|---|---|
Examination of the metabolite hydroxybupropion in the reinforcing and aversive stimulus effects of nicotine in rats.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Bupropion; Male; Nicotine; Rats; Receptors, Nico | 2015 |
Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid.
Topics: Adult; Amniotic Fluid; Antidepressive Agents, Second-Generation; Bupropion; Depression; Female; Feta | 2016 |
Development, validation and application of a comprehensive stereoselective LC/MS-MS assay for bupropion and oxidative, reductive, and glucuronide metabolites in human urine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Chromatography, High Pressure Liquid; Glucuroni | 2016 |
Bupropion and its main metabolite reverse nicotine chronic tolerance in the mouse.
Topics: Analgesics; Animals; Antidepressive Agents; Body Temperature; Bupropion; Dose-Response Relationship, | 2012 |